YIDU TECH (02158) saw its stock price surge by 14.26% in late trading on Tuesday, as investors reacted positively to recent developments in the company's healthcare technology initiatives. The significant uptick in share value reflects growing confidence in YIDU TECH's strategic positioning within the intersection of artificial intelligence and clinical research.

A key driver behind the stock's momentum was the announcement that YIDU TECH's affiliated company, Tianjin Happy Life Technology Co., Ltd., successfully secured a bid for a major clinical research project. The contract, valued at approximately RMB 55.82 million, involves Phase III clinical research for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drops. This substantial project win not only bolsters YIDU TECH's revenue prospects but also underscores the company's growing influence in the biotech research sector.

Further fueling investor enthusiasm was YIDU TECH's recent showcase of its AI capabilities in clinical trials. At the 2025 Tencent Digital Ecosystem Conference Medical Special Session, the company's senior solution expert, Shi Cheng, delivered a compelling presentation on "AI Empowering the Full Process of Clinical Trials." This demonstration highlighted YIDU TECH's technological prowess and its potential to significantly enhance the efficiency and quality of clinical trials through AI applications. The company's focus on leveraging AI to drive high-quality industry development appears to be resonating strongly with market participants, contributing to the notable surge in its stock price.